company background image
6190 logo

PhoenixBio TSE:6190 Stock Report

Last Price

JP¥487.00

Market Cap

JP¥2.0b

7D

1.5%

1Y

-17.7%

Updated

27 Mar, 2024

Data

Company Financials

6190 Stock Overview

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan.

6190 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health5/6
Dividends0/6

PhoenixBio Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PhoenixBio
Historical stock prices
Current Share PriceJP¥487.00
52 Week HighJP¥628.00
52 Week LowJP¥442.00
Beta0.46
1 Month Change2.10%
3 Month Change5.41%
1 Year Change-17.74%
3 Year Change-20.94%
5 Year Change-32.83%
Change since IPO-82.91%

Recent News & Updates

Recent updates

Shareholder Returns

6190JP Life SciencesJP Market
7D1.5%1.0%1.0%
1Y-17.7%-29.6%38.6%

Return vs Industry: 6190 exceeded the JP Life Sciences industry which returned -29.6% over the past year.

Return vs Market: 6190 underperformed the JP Market which returned 38.6% over the past year.

Price Volatility

Is 6190's price volatile compared to industry and market?
6190 volatility
6190 Average Weekly Movement4.5%
Life Sciences Industry Average Movement6.0%
Market Average Movement3.9%
10% most volatile stocks in JP Market8.3%
10% least volatile stocks in JP Market2.1%

Stable Share Price: 6190 has not had significant price volatility in the past 3 months.

Volatility Over Time: 6190's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200265Takashi Shimadahttps://www.phoenixbio.co.jp

PhoenixBio Co., Ltd. provides contract study services for drug discovery and development primarily in Japan. The company uses PXB-mouse, a chimeric mouse with a humanized liver for use in drug development experiments; and in vitro studies using fresh human hepatocytes taken from PXB-cells. The chimeric mouse model with a humanized liver is used for in vivo studies in gene therapeutics, NASH/NAFLD drug development programs, anti-viral therapeutic tests, DMPK/toxicity studies, and custom transplantations.

PhoenixBio Co., Ltd. Fundamentals Summary

How do PhoenixBio's earnings and revenue compare to its market cap?
6190 fundamental statistics
Market capJP¥1.97b
Earnings (TTM)JP¥114.00m
Revenue (TTM)JP¥1.79b

17.2x

P/E Ratio

1.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6190 income statement (TTM)
RevenueJP¥1.79b
Cost of RevenueJP¥582.00m
Gross ProfitJP¥1.21b
Other ExpensesJP¥1.10b
EarningsJP¥114.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 15, 2024

Earnings per share (EPS)28.30
Gross Margin67.52%
Net Profit Margin6.36%
Debt/Equity Ratio28.2%

How did 6190 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.